Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

BTMD

STRONG BUYFLAG

biote Corp. · Healthcare · United States · $81M · Avg Vol: $805K/d

96
StockRank
Get insider-trade alerts
Q
81
V
77
M
44
P/E (TTM)
5.7x
ROE
D/E
Dividend %
AI CONVICTION THESIS

biote Corp. provides hormone-pellet therapy training and products to practitioners, and while quality and value screen well, the company has a nameable governance problem: a protracted public dispute with its founder over control and board composition, alongside a complex up-C share structure, on a roughly $64M market value. Momentum is weak (M40). No accounting failure is known, so this is a flag rather than a removal.

COMPANY DESCRIPTION

biote Corp. is a healthcare company specializing in preventive medicine and hormone optimization therapies through its proprietary training, software, and pellet products. The company's competitive moat is its extensive network of trained, certified practitioners and a highly scalable, recurring-revenue business model. Biote operates as a market leader in the specialized field of bioidentical hormone replacement therapy.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue165.0M185.4M197.2M192.2M5.2%188.2M190.6M204.6M3.2%
EPS-0.040.130.090.86157.2%0.440.720.870.7%
Shares30.3M34.3M31.5M30.7M+1.3%30.3M
Debt120.4M114.9M110.9M109.9M-3.0%108.4M
Equity-44.5M-29.4M-105.9M-58.5M
Op CF-9.2M26.9M45.2M35.2M14.4%32.6M
Inv CF-1.8M-2.7M-18.8M-6.9M
Fin CF63.5M-14.4M-76.1M-43.6M
Loading 1Y...
PRICE (1Y)-5.3%
1.671.882.092.312.52Jun 12Jul 7Jul 27
SMA 50SMA 200
Close
$2.33
RSI (14)
54.3
52W High
$4.75
From 52W High
0.5%

SCORE BREAKDOWN

Quality
81
ROIC
53.5%99.3
ROE
neg eq95.0
GP/Assets
122.6%98.6
Op. Margin
9.8%66.2
FCF/Assets
28.1%98.0
Piotroski
783.4
Int. Cover
3.3x47.3
D/E Ratio
neg eq47.3
Current Ratio
1.29x19.3
Value
77
P/E (TTM)
5.7x96.7
EV/EBITDA
5.7x89.4
P/FCF
2.7x96.9
P/B
-1.3x25.0
P/S
0.5x93.0
Div Yield
N/A
Momentum
44
52W High %
49%25.1
RS 6M
-2%70.8
SMA 50/200
0.96x56.6
EPS Rev 4W
0.0%62.6
EPS Rev 12W
N/A
EPS Improve
+30%41.9
Q Growth
-83%2.9

FUNDAMENTALS

Market Cap
$81M
P/E (Forward)
4.4x
Gross Margin
70.1%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BTMD are excluded.

TickerCompanyMkt CapStockRankSignal
BTMDbiote Corp.(you)$81M96STRONG BUY
JYNTThe Joint Corp.$119M75BUY
CCRNCross Country Healthcare, Inc.$428M87STRONG BUY
WWWW International, Inc.$133M57HOLD
CYHCommunity Health Systems, Inc.$385M78BUY
PARKPark Dental Partners, Inc.$85M44HOLD
NUTXNutex Health Inc.$1.0B99STRONG BUY
AMNAMN Healthcare Services, Inc.$1.3B95STRONG BUY
ARDTArdent Health, Inc.$1.5B94STRONG BUY
DCGODocGo Inc.$59M41HOLD

Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%

biote Corp. (BTMD) — Stock Score Summary

biote Corp. (BTMD) has a MoatMap StockRank of 96/100 based on Quality (81/100), Value (77/100), and Momentum (44/100) factor scores. The current signal is STRONG BUY. biote Corp. provides hormone-pellet therapy training and products to practitioners, and while quality and value screen well, the company has a nameable governance problem: a protracted public dispute with its founder over control and board composition, alongside a complex up-C share structure, on a roughly $64M market value. Momentum is weak (M40). No accounting failure is known, so this is a flag rather than a removal.

biote Corp. is a healthcare company specializing in preventive medicine and hormone optimization therapies through its proprietary training, software, and pellet products. The company's competitive moat is its extensive network of trained, certified practitioners and a highly scalable, recurring-revenue business model. Biote operates as a market leader in the specialized field of bioidentical hormone replacement therapy.

Key Financial Metrics

Price$2.33
Market Cap$81M
P/E (TTM)5.66
P/E (Forward)4.37
Price/Book-1.33
Return on Invested Capital53.5%
Gross Margin70.1%
Operating Margin9.8%
Revenue Growth-8.3%
Free Cash Flow$30M

biote Corp. operates in the Medical Care Facilities industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is biote Corp.’s (BTMD) StockRank?
MoatMap’s StockRank for biote Corp. (BTMD) is 96/100, with a Strong Buy signal. It is a composite of Quality (81), Value (77), and Momentum (44) factor ranks across MoatMap’s 20,000+ stock universe.
Does biote Corp. have an economic moat?
biote Corp. (BTMD) has a Quality factor score of 81/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is biote Corp. a buy, hold, or sell?
MoatMap’s current signal for biote Corp. (BTMD) is Strong Buy, based on a StockRank of 96/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is biote Corp. in?
biote Corp. (BTMD) operates in the Healthcare sector, specifically the Medical Care Facilities industry (United States).